Keros Therapeutics (KROS) Competitors $13.83 +0.09 (+0.66%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$13.80 -0.03 (-0.25%) As of 10/17/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. MLYS, OGN, RXRX, CPRX, ALVO, MESO, BLTE, ARQT, AGIO, and IRONShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Mineralys Therapeutics (MLYS), Organon & Co. (OGN), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Mesoblast (MESO), Belite Bio (BLTE), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Mineralys Therapeutics Organon & Co. Recursion Pharmaceuticals Catalyst Pharmaceuticals Alvotech Mesoblast Belite Bio Arcutis Biotherapeutics Agios Pharmaceuticals Disc Medicine Keros Therapeutics (NASDAQ:KROS) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. Which has higher valuation & earnings, KROS or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than Keros Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$3.55M158.25-$187.35M$0.3144.61Mineralys TherapeuticsN/AN/A-$177.81M-$3.56-12.24 Is KROS or MLYS more profitable? Keros Therapeutics has a net margin of 8.06% compared to Mineralys Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 2.96% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics8.06% 2.96% 2.74% Mineralys Therapeutics N/A -70.44%-65.51% Which has more risk and volatility, KROS or MLYS? Keros Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Do institutionals & insiders hold more shares of KROS or MLYS? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer KROS or MLYS? Keros Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 116.92%. Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential downside of 0.14%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 1 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.40Mineralys Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media refer more to KROS or MLYS? In the previous week, Mineralys Therapeutics had 2 more articles in the media than Keros Therapeutics. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 8 mentions for Keros Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.32 beat Keros Therapeutics' score of 0.15 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryKeros Therapeutics beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$558.06M$3.39B$6.09B$10.49BDividend YieldN/A2.28%5.73%4.81%P/E Ratio44.6122.4484.5227.09Price / Sales158.25429.44568.62202.80Price / CashN/A46.5937.1661.22Price / Book0.9810.4112.246.52Net Income-$187.35M-$52.47M$3.32B$276.75M7 Day Performance-11.91%2.32%1.25%1.97%1 Month Performance-13.78%11.14%6.28%2.23%1 Year Performance-77.42%11.15%59.92%35.58% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.6945 of 5 stars$13.83+0.7%$30.00+116.9%-77.4%$558.06M$3.55M44.61100News CoverageInsider TradeMLYSMineralys Therapeutics1.944 of 5 stars$39.39+5.1%$43.50+10.4%+213.8%$2.61BN/A-11.0628News CoverageInsider TradeOGNOrganon & Co.4.8583 of 5 stars$9.91-3.2%$17.33+74.9%-47.4%$2.58B$6.40B3.684,000RXRXRecursion Pharmaceuticals2.2325 of 5 stars$5.91-3.0%$7.25+22.7%-10.5%$2.57B$58.84M-3.32400Trending NewsAnalyst RevisionGap DownCPRXCatalyst Pharmaceuticals4.8274 of 5 stars$20.82+2.1%$33.20+59.5%-2.9%$2.55B$491.73M12.6280Positive NewsALVOAlvotech3.6092 of 5 stars$8.30-4.4%$14.00+68.7%-29.7%$2.50B$560.10M36.091,032Analyst ForecastMESOMesoblast1.7176 of 5 stars$19.53-1.1%$24.00+22.9%+71.9%$2.50B$17.20M0.0080Gap DownBLTEBelite Bio1.6449 of 5 stars$78.50+0.6%$96.00+22.3%+56.6%$2.50BN/A-50.6510News CoverageGap UpARQTArcutis Biotherapeutics1.4064 of 5 stars$20.71-2.5%$19.80-4.4%+120.0%$2.48B$196.54M-27.61150Analyst ForecastAGIOAgios Pharmaceuticals4.3282 of 5 stars$42.43-0.4%$56.00+32.0%-4.1%$2.47B$40.88M3.86390News CoverageIRONDisc Medicine2.6981 of 5 stars$70.75+0.7%$98.30+38.9%+78.1%$2.46BN/A-15.8330Trending NewsAnalyst ForecastInsider TradeGap Up Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Organon & Co. Alternatives Recursion Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Alvotech Alternatives Mesoblast Alternatives Belite Bio Alternatives Arcutis Biotherapeutics Alternatives Agios Pharmaceuticals Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
